Dry Powder Inhaler unveiled at Respiratory Drug Delivery Conference Europe

H&T Presspart, the world’s leading manufacturer of components for metered dose inhalers (MDIs), today announced a collaborative partnership with Hovione Technology, supporting a strategic plan to expand its portfolio of novel drug delivery systems in respiratory care.

As part of the partnership, H&T Presspart has acquired the global rights to manufacture and commercialise a capsule-based dry powder inhaler (DPI) originated by Hovione. H&T Presspart unveiled an enhanced version of the DPI, which will be marketed as PowdAir Plus, at Respiratory Drug Delivery (RDD) Europe 2017 on 26 April.

“This is a strategically significant partnership for H&T Presspart and underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialisation of novel drug delivery solutions for respiratory patients,” said Peter Schmelzer, Chairman of H&T Presspart. “This partnership supports our strategy to respond to the rapidly growing demand for dry powder inhalers across a range of needs, with this collaboration focused on providing a solution for developing markets.”

Launch of PowdAir Plus

PowdAir Plus is a novel, sleek, patented capsule-based DPI designed for advanced simplicity, ease of use and affordability, making it ideal for developing markets, where demand for respiratory treatments is growing rapidly. Neat and compact, PowdAir Plus is both attractive and highly portable, and the novel all-plastic, four-component design minimises manufacturing assembly and production costs, whilst maximising ease of use.
PowdAir Plus dry powder inhaler

“We are delighted with the collaboration with H&T Presspart. With our expertise in DPI invention, design and development and Presspart’s mastery of large scale industrialization and global distribution, we are very confident about success,” said Peter Villax, CEO of Hovione Technology, a company founded by the shareholders of Hovione, a 58-year old manufacturer of Active Pharmaceutical Ingredients (APIs).

Pharmaceutical companies that work with H&T Presspart on this device can also access Hovione’s expertise in API formulation and manufacturing alongside H&T Presspart’s state- of-the-art manufacturing capabilities and experience in industrialising products for pharmaceutical companies.

PowdAir Plus has been developed in response to the recognised need to offer patients in developing markets more choice of DPIs. Most DPIs have been designed for developed markets and incorporate multiple components and complex mechanics.

PowdAir Plus is a complete unit with has no metal or separate parts, and was designed to be robust to withstand the mechanical stresses of frequent use. Throughout the design process, functionality was of utmost importance and PowdAir Plus delivers an effective dose of medication with each capsule in line with expected market performance. It is compatible with all capsule types (i.e. gelatine and HPMC) in size 3, so can be used with any dry powder medicines.

A particularly novel design feature is the way in which the device opens the capsule once the tray is closed, removing the need for patients to actively pierce the capsule and reducing the number of operational steps. By enhancing ease of use, the design also removes the risk of errors that may affect a treatment’s efficacy.

“As demand in developing markets is increasing, pharmaceutical companies are looking for devices that deliver reliable performance and meet high patient expectations for ease of use, but at a reduced cost,” said Peter Schmelzer.

About H&T Presspart

H&T Presspart offers pharmaceutical customers high-precision injection moulded plastic components and deep drawn metal cans for respiratory drug delivery systems, with more than 45 years’ experience and a worldwide reputation for competence, quality and innovation in pharmaceutical and industrial sectors. H&T Presspart Inhalation Product Technology Centre (IPTC) supports new product developments and strategic initiatives with its customers. Founded in 1970 and acquired by the Heitkamp and Thumann group in 2002, H&T Presspart has 3 European manufacturing sites in Germany, Spain and the UK, with Sales offices in China, India, South America and the USA.

presspart.com | Powdair@presspart.com | @presspart

About Hovione Technology

Hovione Technology offers access to innovative, attractive and globally competitive inhalation devices that maximize simplicity of use, safety, drug delivery performance and industrial manufacturability. With more than 20 years’ experience in inhalation device development and a track record for developing novel and effective inhalation devices that have been successfully marketed, Hovione Technology offers development services and access to a family of disruptive, patent-granted inhalers for both acute and chronic treatments.

hovionetechnology.com | jventura@hovionetechnology.com